Medtech VC investment reached $4.1 billion in Q2 2025, with the sector on pace to its second-best year on record, trailing only 2021. Despite a drop in deal count, capital remains concentrated in late-stage and top-tier companies, with the surgical devices & tools segment commanding nearly half of all VC dollars in Q2. Neuralink’s $650 million Series E led a $1.2 billion funding spree among innovators in the surgical space. Meanwhile, Function Health’s $300 million Series B and acquisition of Ezra highlights strategic convergence in diagnostics. On the PE side, 2025 is also shaping up to be a strong year, even as exit activity stalls. Investors are recalibrating to longer timelines, fueling a sharp rise in venture-growth-stage deals.
Read the full article: PitchBook Q2 2025 Medtech VC and PE Trends //
Source: https://pitchbook.com/news/reports/q2-2025-medtech-vc-and-pe-trends